Review
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Pharmacol. Dec 9, 2013; 2(4): 92-99
Published online Dec 9, 2013. doi: 10.5497/wjp.v2.i4.92
Neurotrophic and metabotrophic potential of nerve growth factor and brain-derived neurotrophic factor: Linking cardiometabolic and neuropsychiatric diseases
Stanislav Yanev, Luigi Aloe, Marco Fiore, George N Chaldakov
Stanislav Yanev, Institute of Neurobiology, Department of Drug Toxicology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria
Luigi Aloe, Marco Fiore, Institute of Cellular Biology and Neurobiology, National Research Council, I-00168 Rome, Italy
George N Chaldakov, Laboratory of Cell Biology, Department of Anatomy and Histology, Medical University, BG-9002 Varna, Bulgaria
Author contributions: All the authors contributed to this paper equally.
Correspondence to: George N Chaldakov, MD, PhD, Laboratory of Cell Biology, Department of Anatomy and Histology, Medical University, 55 Marin Drinov Street, BG-9002 Varna, Bulgaria. chaldakov@yahoo.com
Telephone: +359-52-754394 Fax: +359-52-650019
Received: July 30, 2013
Revised: September 20, 2013
Accepted: October 16, 2013
Published online: December 9, 2013
Processing time: 140 Days and 23.6 Hours
Core Tip

Core tip: Previously we reviewed an enlarged list of metabotrophins including the adipose-produced nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), leptin and adiponectin as relevant to cardiometabolic, neurological and psychiatric diseases (Riv Psichiatr 2009; 44: 79-87). Now we update the growing body of evidence that NGF-BDNF/TrkA, B dysfunction may synergistically leads to both cardiometabolic and neuropsychiatric diseases. This may help to construct a conceptually novel therapeutic approach for future studies in the field of translational pharmacology of NGF and BDNF.